Distribution of new-onset ExRA manifestations during the followup period. Values are n.
| Variable | All | During Anti-TNF Treatment | Not during Anti-TNF Treatment |
|---|---|---|---|
| Any severe ExRA manifestation during followup* | 124 | 17 | 104 |
| Pericarditis | 21 | 0 | 21 |
| Pleuritis | 41 | 7 | 34 |
| Felty’s syndrome | 11 | 1 | 10 |
| Interstitial lung disease | 19 | 3 | 16 |
| Glomerulonephritis | 1 | 0 | 1 |
| Neuropathy | 13 | 1 | 12 |
| Scleritis, episcleritis, or retinal vasculitis | 21 | 6 | 14 |
| Major cutaneous vasculitis | 31 | 3 | 27 |
| Vasculitis involving other organs | 4 | 0 | 4 |
↵* Some patients had more than 1 severe ExRA during followup. Three patients had ExRA during or after treatment with biologic DMARD other than TNF inhibitors. There were no cases of retinal vasculitis. ExRA: extraarticular rheumatoid arthritis; DMARD: disease-modifying antirheumatic drugs; TNF: tumor necrosis factor.